Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II.

The Bromodomain-containing protein 4 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Bromodomain-containing protein 4, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Bromodomain-containing protein 4 and features dormant and discontinued projects.

Key Therapy Areas in the Bromodomain-containing protein 4 Pipeline Drugs Market

In the Bromodomain-containing protein 4 pipeline drugs market the key therapy areas are Oncology, Infectious Disease, Dermatology, Immunology, Cardiovascular, Genetic Disorders, Genito Urinary System and Sex Hormones, and Musculoskeletal Disorders.

Bromodomain-Containing Protein 4 Pipeline Drugs Market, by Therapy Areas

Bromodomain-Containing Protein 4 Pipeline Drugs Market, by Therapy Areas

For more therapy arae insights, download a free report sample

Key MoA in the Bromodomain-Containing Protein 4 Pipeline Drugs Market

In the Bromodomain-Containing Protein 4 pipeline drugs market, the key MoA is Bromodomain Containing Protein 4 Inhibitor.

Bromodomain-Containing Protein 4 Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Bromodomain-Containing Protein 4 pipeline drugs market are oral, parenteral, inhalational, intratumor, intravenous, subcutaneous, and topical. Oral has the maximum number of pipeline products.

Bromodomain-Containing Protein 4 Pipeline Drugs Market Analysis, by RoA

Bromodomain-Containing Protein 4 Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the BRD4 Pipeline Drugs Market

The key molecule types in the Bromodomain-Containing Protein 4 pipeline drugs market are Small Molecule, Antisense RNAi Oligonucleotide, and Gene-Modified Cell Therapy.

Bromodomain-Containing Protein 4 Pipeline Drugs Market, by Molecule Type

Bromodomain-Containing Protein 4 Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Bromodomain-Containing Protein 4 Pipeline Drugs Market

The major companies in the BRD4 pipeline drugs market are Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Bromodomain Pharmaceuticals Inc, C4 Therapeutics Inc, Checkpoint Therapeutics Inc, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Constellation Pharmaceuticals Inc, AbbVie Inc, Amgen Inc and ConverGene LLC.

Bromodomain-Containing Protein 4 Pipeline Drugs Market, by Major Companies

Bromodomain-Containing Protein 4 Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Bromodomain-Containing Protein 4 Pipeline Drugs Market Overview

Key Therapy Areas Oncology, Infectious Disease, Dermatology, Immunology, Cardiovascular, Genetic Disorders, Genito Urinary System and Sex Hormones, and Musculoskeletal Disorders
Key Mechanisms of action Bromodomain Containing Protein 4 Inhibitor
Key Routes of Administration Oral, Parenteral, Inhalational, Intratumor, Intravenous, Subcutaneous, and Topical
Key Molecule Types Small Molecule, Antisense RNAi Oligonucleotide, and Gene-Modified Cell Therapy
Major Companies Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Bromodomain Pharmaceuticals Inc, C4 Therapeutics Inc, Checkpoint Therapeutics Inc, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Constellation Pharmaceuticals Inc, AbbVie Inc, Amgen Inc and ConverGene LLC

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bromodomain-Containing Protein 4
  • The pipeline guide reviews pipeline therapeutics for Bromodomain-Containing Protein 4 by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bromodomain-Containing Protein 4 therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bromodomain-Containing Protein 4 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Bromodomain-Containing Protein 4

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bromodomain-Containing Protein 4
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bromodomain-Containing Protein 4 pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Amgen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Bromodomain Pharmaceuticals Inc
C4 Therapeutics Inc
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Constellation Pharmaceuticals Inc
ConverGene LLC
CSPC Pharmaceutical Group Ltd
Epigene Therapeutics Inc
Kainos Medicine Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
Nuvation Bio Inc
OHM Oncology
Phio Pharmaceuticals Corp
Plexium Inc
Plexxikon Inc
Ranok Therapeutics Co Ltd
Red Glead Discovery AB
Resverlogix Corp
Roivant Sciences Ltd
Shanghai Haihe Biopharma Co Ltd
Sierra Oncology Inc
SignalRx Pharmaceuticals Inc
VYNE Therapeutics Inc
Zenith Epigenetics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Overview

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Companies Involved in Therapeutics Development

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Drug Profiles

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Dormant Products

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Discontinued Products

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) – Product Development Milestones

Featured News & Press Releases

Apr 08, 2022: Phio Pharmaceuticals presents positive new data on PH-894 demonstrating antitumor efficacy in model of PD-1 refractory disease at the AACR Annual Meeting 2022

Mar 30, 2022: VYNE Reports positive preclinical data for intra-articular injection of pan-BET inhibitor, VYN201, in an in vivo model of rheumatoid arthritis

Mar 17, 2022: Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Mar 08, 2022: Phio Pharmaceuticals announces upcoming presentation of PH-894 data at the AACR Annual Meeting 2022

Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo

Feb 22, 2022: Zenith Epigenetics announces dosing of first cancer patient with a combination of ZEN-3694 + Bristol Myers Squibb’s immune checkpoint inhibitor OPDIVO

Feb 18, 2022: Resverlogix expands Phase IIb apabetalone trial for Covid-19

Feb 15, 2022: Ranok Therapeutics to present at BMO Biopharma spotlight series on protein degraders and other Next Gen

Jan 24, 2022: Ranok Therapeutics announces U.S. FDA clearance to proceed with its first-in-human trial of RNK05047 in patients With advanced solid tumor cancers and lymphomas (CHAMP-1)

Jan 21, 2022: US FDA clears Nuvation Bio’s application for solid tumour therapy

Jan 19, 2022: Resverlogix starts Phase IIb oral Covid-19 drug trial

Jan 18, 2022: Resverlogix announces commencement of patient enrollment and dosing in a phase 2b trial for a promising Canadian-developed COVID-19 treatment

Dec 12, 2021: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis

Nov 04, 2021: MorphoSys to present MANIFEST data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting

Nov 04, 2021: Lead BET inhibitor, VYN201, demonstrates improvement in reducing fibrotic tissue mass and overall skin repair outcomes in preclinical study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Products under Development by Companies, 2022 (Contd..9)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AbbVie Inc, 2022

Pipeline by Amgen Inc, 2022

Pipeline by Boehringer Ingelheim International GmbH, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Bromodomain Pharmaceuticals Inc, 2022

Pipeline by C4 Therapeutics Inc, 2022

Pipeline by Checkpoint Therapeutics Inc, 2022

Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022

Pipeline by Constellation Pharmaceuticals Inc, 2022

Pipeline by ConverGene LLC, 2022

Pipeline by CSPC Pharmaceutical Group Ltd, 2022

Pipeline by Epigene Therapeutics Inc, 2022

Pipeline by Kainos Medicine Inc, 2022

Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2022

Pipeline by Nuvation Bio Inc, 2022

Pipeline by OHM Oncology, 2022

Pipeline by Phio Pharmaceuticals Corp, 2022

Pipeline by Plexium Inc, 2022

Pipeline by Plexxikon Inc, 2022

Pipeline by Ranok Therapeutics Co Ltd, 2022

Pipeline by Red Glead Discovery AB, 2022

Pipeline by Resverlogix Corp, 2022

Pipeline by Roivant Sciences Ltd, 2022

Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022

Pipeline by Sierra Oncology Inc, 2022

Pipeline by SignalRx Pharmaceuticals Inc, 2022

Pipeline by VYNE Therapeutics Inc, 2022

Pipeline by Zenith Epigenetics Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Dormant Products, 2022 (Contd..4)

Dormant Products, 2022 (Contd..5)

Discontinued Products, 2022

Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.